Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Type
News Topics
- (-) Biomedical (3)
- 3-D Printing/Advanced Manufacturing (16)
- Advanced Reactors (4)
- Artificial Intelligence (10)
- Bioenergy (10)
- Biology (5)
- Buildings (2)
- Chemical Sciences (20)
- Climate Change (5)
- Composites (3)
- Computer Science (15)
- Coronavirus (2)
- Critical Materials (8)
- Cybersecurity (11)
- Decarbonization (5)
- Energy Storage (19)
- Environment (8)
- Exascale Computing (1)
- Frontier (2)
- Fusion (4)
- Grid (3)
- High-Performance Computing (3)
- Isotopes (6)
- ITER (1)
- Machine Learning (6)
- Materials (38)
- Materials Science (36)
- Microscopy (12)
- Molten Salt (2)
- Nanotechnology (21)
- National Security (11)
- Net Zero (1)
- Neutron Science (20)
- Nuclear Energy (11)
- Partnerships (11)
- Physics (15)
- Polymers (6)
- Quantum Computing (1)
- Quantum Science (10)
- Renewable Energy (1)
- Security (5)
- Space Exploration (2)
- Summit (1)
- Sustainable Energy (9)
- Transformational Challenge Reactor (2)
- Transportation (5)
Media Contacts
Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.